Track PepGen Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

PepGen Inc. Common Stock PEPG · Stock Open PepGen Inc. Common Stock in new tab

1.88 USD
EPS
-1.50
P/B
0.92
ROE
-68.40
Beta
1.88
Target Price
10.25 USD
Loading chart...
Key Metrics
Earnings dateAug. 6, 2026
EPS-1.50
Book Value1.94
Price to Book0.92
Debt/Equity12.36
% Insiders0.234%
Estimates
Forward P/E-1.45
Forward EPS-1.23
Target Mean Price10.25

DCF Valuation

Tweak assumptions to recompute fair value for PepGen Inc. Common Stock (PEPG)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

PepGen Inc. Common Stock Logo PepGen Inc. Common Stock Analysis (PEPG)

United States Health Care Official Website Stock

Is PepGen Inc. Common Stock a good investment? PepGen Inc. Common Stock (PEPG) is currently trading at 1.88 USD. Market analysts have a consensus price target of 10.25 USD. This suggests a potential upside from current levels.

Earnings Schedule: PepGen Inc. Common Stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -1.23.

Investor FAQ

Does PepGen Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is PepGen Inc. Common Stock?

PepGen Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.50.

Company Profile

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Exchange Ticker
NMS (United States) PEPG
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion